ReviewAnnals of hematology2022
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Review in Annals of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children
A Prospective, Randomized, Open-Label, Controlled Study of Romiplostim N01 Combined With All-Trans Retinoic Acid Versus Romiplostim N01 Alone for Persistent Isolated Chemotherapy-Induced Thrombocytopenia in Patients With Complete Remission of Gastrointestinal Solid Tumors
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis.The Journal of international medical research · 2023Pooled it
- Efficacy and safety of eltrombopag in combination with cyclosporine A for the treatment of adult refractory primary immune thrombocytopenia: a phase II, multicenter, single-arm, prospective study.Clinical and experimental medicine · 2026Trial
- Evolving Patterns of TPO-RA Use in Children: A Decade of Single-Centre Experience and Narrative Review.International journal of molecular sciences · 2026Review
- Single-Cell Analysis Highlights Pivotal Role of Eosinophil-Basophil Mast Cell Progenitor-Related Mechanism in Primary Immune Thrombocytopenia.International journal of molecular sciences · 2026Article
- A Comparative Analysis of the Efficacy, Safety and Mechanism of Action of Flebogamma DIF, Fostamatinib and Romiplostim in Immune Thrombocytopenia.Life (Basel, Switzerland) · 2026Review
- Optimizing pediatric ITP therapy: a real-world study on plasma concentration-guided eltrombopag dosing.Annals of hematology · 2026Observational
- A Clinician Perspective for a Personalized Approach to Management of Chronic Immune Thrombocytopenia with Targeted Therapies Alone or in Combination.Journal of clinical medicine · 2026Review
- Avatrombopag in heavily pretreated chronic immune thrombocytopenia: a single center experience from Oman.Frontiers in medicine · 2026Article
- Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives.Current opinion in hematology · 2026Review
- Efficacy and Safety of Avatrombopag Treatment in Immune Thrombocytopenia Patients in Poland: A Multicenter Study.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Case Report: Hematopoietic stem cell transplantation for refractory chronic immune thrombocytopenia in a child.Frontiers in immunology · 2026Review
- Refractory ITP: revisiting definitions, diagnostics, and management paradigms.Hematology. American Society of Hematology. Education Program · 2025Review
- When the victim becomes the villain: Platelets as drivers of immune dysregulation in ITP.Journal of translational autoimmunity · 2025Review
- Review
- Influence of Anxiety Level and Degree of Alexithymia on Quality of Life in Adult Patients With Primary Immune Thrombocytopenia.Actas espanolas de psiquiatria · 2025Article
- The Complex Role of MAPK/ERK Signaling Pathway in Different Types of Thrombocytopenia.Current issues in molecular biology · 2025Review
- Assessing serum thrombopoietin for enhanced diagnosis of ITP, AA, and MDS using machine learning: A retrospective cohort study.Annals of hematology · 2025Article
- The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK.Journal of market access & health policy · 2025Article
- CDKN1A as a potential target for Eltrombopag treatment in ITP and its regulation of the communication between macrophages and transitional B cells in ITP.Annals of hematology · 2025Article
- OX40 ligand promotes follicular helper T cell differentiation and development in mice with immune thrombocytopenia.Journal of Zhejiang University. Science. B · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic primary immune thrombocytopenia (ITP) can today benefit from multiple therapeutic approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor agonists (TPO-RA), and splenectomy. However, some ITP patients are unresponsive to multiple lines of therapy with prolonged and severe thrombocytopenia. The diagnosis of refractory ITP is mainly performed by exclusion of other disorders and is based on the clinician's expertise. However, it significantly increases the risk of drug-related toxicity and of bleedings, including life-threatening events. The management of refractory ITP remains a major clinical challenge. Here, we provide an overview of the currently available treatment options, and we discuss the emerging rationale of new therapeutic approaches and their strategic combination. Particularly, combination strategies may target multiple pathogenetic mechanisms and trigger additive or synergistic effects. A series of best practices arising both from published studies and from real-life clinical experience is also included, aiming to optimize the management of refractory ITP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.